Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 08, 2018 ) Market growth can be attributed to factors such as rapid penetration of high and average risk NIPT test, high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT, shifting trend towards child bearing at advanced maternal age (35 years or older), launch of new and advanced NIPT products. With increased patient access to NIPT test, United States NIPT test market is anticipated to have a positive outlook in the coming years.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-DPI-HnM-3127
The research report titled “United States Non-Invasive Prenatal Testing(NIPT) Market Insights, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 – 2023” examines the market, competitive landscape and trends of the United States NIPT Test Market. The study provides an in–depth analysis of the actual and potential NIPT test market.
Key Companies Covered in the Report are as follows:
• Sequenom Laboratories (LabCorp) • Ariosa Diagnostics (Roche) • Illumina • Natera • Quest Diagnostics
Purchase Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-DPI-HnM-3127/ (Priced at USD 1150)
The report provides a decisive view on the NIPT Test volume and market in United States. It also covers reimbursement pattern and offers a clear view of the regulatory landscape in the United States NIPT Test Market. Additionally, the report includes insights into the NIPT implementation in the high-income countries. Key trends in terms of collaboration, partnership, merger & acquisition, venture capital investment distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States NIPT Test Market.
The report concludes with the profiles of major players in the United States NIPT Test Market. The key market players are evaluated on various parameters such as company overview, NIPT test portfolio, NIPT test analysis with volume and market revenue and latest development and trends of the NIPT Test Market.
Key Topics Covered in the Report
• United States Actual NIPT Test Volume & Market Revenue (2015 - 2023) • United States Potential NIPT Test Volume & Market Revenue (2015 - 2023) • United States Average Risk Actual NIPT Test Volume & Market Revenue (2015 - 2023) • United States Average Risk Potential NIPT Test Volume & Market Revenue (2015 - 2023) • United States High Risk Actual NIPT Test Volume & Market Revenue (2015 - 2023) • United States High Risk Potential NIPT Test Volume & Market Revenue (2015 - 2023) • United States NIPT Test Market - Reimbursement & Regulation System • NIPT Test Implementation in High–Income Countries • United States NIPT Test Market - Comparative Test Analysis • United States NIPT Test Market – Major Deal Types • Key Companies Analysis • Key Drivers and Inhibitors of the United States NIPT Test Market
Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-DPI-HnM-3127
Table of Content:
1. Executive Summary 2. United States Non–Invasive Prenatal Testing(NIPT) Market Analysis (2015 – 2023) 2.1 Overall Actual NIPT Test Volume & Forecast 3. Key Drivers and Inhibitors of the United States NIPT Test Market 3.1 Market Drivers 3.2 Inhibitors 4. United States NIPT Test Market: Reimbursement & Regulation System 4.1 Reimbursement System 4.2 Regulation System 5. Non–Invasive Prenatal Testing (NIPT) Implementation – High–Income Countries 5.1 Clinical Issues 6. Competitive Landscape 6.1 Non–Invasive Prenatal Testing(NIPT) – Comparative Analysis 6.2 Non–Invasive Prenatal Testing – Collaboration Deals 7. Key Companies Analysis
Enquiry for Customization@ https://www.qurateresearch.com/report/customize/HnM/QBI-DPI-HnM-3127
List of figures: List of Tables Table 3 1: Maternal Age at Delivery and Risk of Down Syndrome Table 4 1: NIPT Test CMS Price(US$),2017 Table 6 1: Non–Invasive Prenatal Testing – Comparative Tests Analysis Table 6 2: Non–Invasive Prenatal Testing – Collaboration Deals, 2007 – 2017 Table 6 3: Non–Invasive Prenatal Testing – Venture Capital Investment, 2011 – 2015
Qurate Business Intelligence
Nehal Chinoy
+919881074592
nehal@qurateresearch.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|